In the latest trading session, AbbVie (ABBV - Free Report) closed at $87.73, marking a +0.89% move from the previous day. This move outpaced the S&P 500's daily loss of 0.25%. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, lost 0.53%.
Heading into today, shares of the drugmaker had lost 6.58% over the past month, lagging the Medical sector's loss of 1.06% and the S&P 500's loss of 2.35% in that time.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. The company is expected to report EPS of $1.91, up 29.05% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $8.36 billion, up 8.07% from the prior-year quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.92 per share and revenue of $32.78 billion. These results would represent year-over-year changes of +41.43% and +16.17%, respectively.
Investors might also notice recent changes to analyst estimates for ABBV. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.89% higher within the past month. ABBV currently has a Zacks Rank of #3 (Hold).
In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 10.97. This represents a discount compared to its industry's average Forward P/E of 14.74.
Also, we should mention that ABBV has a PEG ratio of 0.83. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.01 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.